CJC-1295 (NO DAC)

CJC-1295 (No DAC), commonly referred to as Modified GRF 1-29 (Mod GRF 1-29), is a synthetic analog of growth hormone-releasing hormone (GHRH). It is designed to interact with GHRH receptors and stimulate the pituitary gland’s endogenous release of growth hormone.

The “No DAC” designation is important because this compound differs substantially from CJC-1295 with DAC. The DAC, or Drug Affinity Complex, is an additional modification that enables albumin binding and significantly prolongs circulation time. CJC-1295 without DAC does not contain this albumin-binding modification and therefore has a substantially shorter duration of activity.

How does CJC-1295 (No DAC) work?

CJC-1295 (No DAC) acts as a GHRH analog, stimulating GHRH receptors involved in the regulation of growth hormone secretion. Activation of these receptors signals growth-hormone-producing cells in the anterior pituitary to release endogenous growth hormone.

Because the no-DAC form lacks the albumin-binding component found in the long-acting DAC version, its pharmacological profile is intended to remain comparatively short-acting. This makes it particularly relevant to research investigating the timing and regulation of growth hormone secretion rather than prolonged GH stimulation.

How is CJC-1295 (No DAC) Used?

CJC-1295 (No DAC) is primarily used as an experimental research compound for investigating GHRH receptor signaling and the growth hormone–IGF-1 axis. Research interest includes the relationship between GHRH stimulation, endogenous growth hormone release, and downstream physiological processes.

It is important to note that the commonly cited human CJC-1295 clinical studies evaluated the DAC-containing version. A 2006 randomized clinical study demonstrated sustained increases in GH and IGF-1 following administration of CJC-1295 with DAC, but those results should not be presented as direct clinical evidence for the no-DAC formulation.

Benefits:

Growth Hormone Research: CJC-1295 (No DAC) is investigated for its ability to stimulate endogenous growth hormone secretion through activation of the GHRH receptor.

GHRH Signaling: The compound provides researchers with a tool for studying GHRH receptor activity and the physiological regulation of pituitary growth hormone release.

GH–IGF-1 Axis Research: Growth hormone stimulates downstream production of insulin-like growth factor-1 (IGF-1), making GHRH analogs useful for investigating interactions between the GH and IGF-1 signaling pathways.

Pulsatile Secretion Research: The short-acting nature of the no-DAC form makes it particularly interesting for research concerning transient or pulsatile growth hormone signaling. However, claims that it precisely reproduces normal physiological GH pulses have not been established through controlled human trials of CJC-1295 (No DAC).

Metabolic & Physiological Research: The GH–IGF-1 system influences numerous physiological processes, including protein metabolism, tissue growth, and energy regulation. CJC-1295 (No DAC) may therefore serve as an experimental tool for studying these interconnected pathways.

Research Considerations:

CJC-1295 (No DAC) should not be confused with CJC-1295 with DAC. Although the compounds share a GHRH-related backbone, their pharmacokinetic profiles are substantially different.

The strongest published human evidence associated with the CJC-1295 name comes from studies of the DAC-containing compound. In those studies, subcutaneous CJC-1295 produced dose-dependent increases in GH and IGF-1, with a reported half-life of approximately 5.8–8.1 days. These findings describe the long-acting DAC formulation and cannot be directly applied to CJC-1295 (No DAC).

Current evidence reviews indicate that CJC-1295 (No DAC) remains essentially uncharacterized in controlled human clinical research. Consequently, claims concerning improvements in body composition, athletic performance, recovery, or other clinical outcomes should be treated as unconfirmed rather than established benefits.

Dosage:

There is no established or FDA-approved human dosage regimen for CJC-1295 (No DAC). Published dosing information for the DAC formulation should not be transferred to the no-DAC form because the two compounds have different pharmacokinetic characteristics.

Experimental applications should follow the specific research protocol and formulation being investigated rather than generalized dosing recommendations.

Conclusions:

CJC-1295 (No DAC), also known as Modified GRF 1-29, is a short-acting GHRH analog that has generated interest in research involving endogenous growth hormone secretion and GH–IGF-1 signaling.

Its primary research value lies in investigating GHRH-mediated stimulation of growth hormone and the dynamics of short-acting GH secretagogues. However, the distinction between the no-DAC and DAC formulations is critical: the published human clinical evidence for CJC-1295 largely concerns the long-acting DAC version rather than CJC-1295 (No DAC).

Further controlled research is needed to establish the pharmacokinetics, safety, biological effects, and potential clinical applications of CJC-1295 (No DAC).

CJC-1295 (No DAC) is intended for research purposes and should not be considered a treatment or cure for any medical condition.